Comparing Amarillo Biosciences (OTCMKTS:AMAR) & Spruce Biosciences (NASDAQ:SPRB)

Amarillo Biosciences (OTCMKTS:AMAR) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Volatility and Risk

Amarillo Biosciences has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 3.62, suggesting that its share price is 262% more volatile than the S&P 500.

Profitability

This table compares Amarillo Biosciences and Spruce Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amarillo Biosciences	-41,453.98%	N/A	-574.29%
Spruce Biosciences	N/A	-203.99%	-127.96%

Valuation and Earnings

This table compares Amarillo Biosciences and Spruce Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarillo Biosciences	$20,000.00	0.00	-$1.45 million	N/A	N/A
Spruce Biosciences	$4.91 million	18.87	-$38.97 million	($51.72)	-1.31

Amarillo Biosciences has higher earnings, but lower revenue than Spruce Biosciences.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Amarillo Biosciences and Spruce Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarillo Biosciences	0	0	0	0	0.00
Spruce Biosciences	1	3	4	0	2.38

Spruce Biosciences has a consensus price target of $170.10, indicating a potential upside of 151.50%. Given Spruce Biosciences’ stronger consensus rating and higher possible upside, analysts clearly believe Spruce Biosciences is more favorable than Amarillo Biosciences.

Insider & Institutional Ownership

91.7% of Spruce Biosciences shares are owned by institutional investors. 34.4% of Amarillo Biosciences shares are owned by company insiders. Comparatively, 6.9% of Spruce Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Spruce Biosciences beats Amarillo Biosciences on 8 of the 11 factors compared between the two stocks.

About Amarillo Biosciences

Amarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.

About Spruce Biosciences

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.